Skip to main content

Table 4 B cell lymphoma antigens targeted by CAR-T cells

From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

CAR-T antigen Clinical study Disease
CD19 Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma B-cell lymphoma;
BAFF-R Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions B- ALL;
CD20 Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma R/R DLBCL
CD22 CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL R/R DLBCL
CD79b Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas B-cell lymphoma
CD37 Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma R/R B-NHL
PD-1 CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma PD-L1 Positive B-Cell Lymphoma
Igκ T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells Low-grade NHL;
  1. Abbreviations: CAR chimeric antigen receptor, B-ALL B-cell acute lymphoblastic leukemia, B-NHL B-cell non-Hodgkin lymphoma, R/R DLBCL relapsed and refractory diffuse large B cell lymphoma, PD-1 programmed cell death protein-1, PD-L1 programmed death ligand 1, B-CLL B-cell chronic lymphocytic leukemia